Realizing the promise of pharmacogenomics: Opportunities and challenges

Biotechnology Law Report

Volumn 26, Issue 3, 2007, Pages 261-291

  Tuckson, Reed V ^a   Au, Sylvia Mann ^b   Berry, Cynthia E ^c   McGrath, Barbara Burns ^d   Chen, Chira ^e   Evans, James P ^f   FitzGerald, Kevin ^g   Lauler, David P ^g   Ferreira Gonzalez, Andrea ^h  

^a UNITEDHEALTH GROUP   (United States)

^b HAWAII STATE DEPARTMENT OF HEALTH   (United States)

^c Powell Goldstein Frazer and Murphy   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547436902     PISSN: 0730031X     EISSN: None     Source Type: Journal    
DOI: 10.1089/blr.2007.9956     Document Type: Review

References (186)

1. Agency for Healthcare Research and Quality. Centers for Education and Research on Therapeutics: overview. AHRQ Publication No. 07-P000-EF, 2007; www.ahrq.gov/clinic/certsovr.htm.
2. Agency for Healthcare Research and Quality. DEcIDE Network & CERTs, 2007; http://effectivehealthcare.ahrq.gov/decide/index, cfm.
3. Agency for Healthcare Research and Quality. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146, 2007; www.ahrq.gov/clinic/tp/cyp450tp.htm.
4. Agendia. About MammaPrint. Amsterdam, The Netherlands, 2007; www.agendia.com/index.php?option=com_content& task=view&id=6&Itemid= 29.
5. Altman RB, Klein TE. Challenges for biomedical informatics and pharmacogenomics. Ann Rev Pharmacol Toxicol 2002;42:113-33.
6. Anonymous. Crossing the quality chasm: a new health system for the 21st century, 2001.
7. Anonymous. To err is human: building a safer health system, 2000.
8. Asch SM, Kerr EA, Keesey J, et al. Who is at greatest risk of receiving poor-quality health care? N Engl J Med 2006;354:1147-56.
9. Bare J. Making sense of health plan denials. Fam Pract Manag 2001;8:39-42.
10. Bartfai T. Pharmacogenomics in drug development: societal and technical aspects. Pharmacogenomics J 2004;4:226-32.
11. Barton JH. Patents, genomics, research, and diagnostics. Acad Med 2002;77:1339-47.
12. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
13. Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol Sci 2006;27:498-502.
14. Biotechnology Industry Organization. Off-label use of anticancer therapies: physician prescribing trends and the impact of payer coverage policy, 2005; www.bio.org/speeches/pubs/CovanceReport.pdf.
15. Borchardt PE. Pharmacogenomics: an in-house advantage? Drug Discovery Today 2006;11(12):1-3.
16. Burke W, Atkins D, Gwinn M, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002;156:311-8.
17. Califf RM. Defining the balance of risk and benefit in the era of genomics and proteomics. Health Affairs 2004;23:77-87.
18. Centers for Disease Control and Prevention. Evaluation of genomic applications in practice and prevention (EGAPP): implementation and evaluation of a model approach, 2007; www.cdc.gov/genomics/gtesting/egapp.htm.
19. Centers for Disease Control and Prevention. HuGE reviews; www.cdc.gov/genomics/hugenet/reviews.htm.
20. Centers for Disease Control and Prevention: Welcome to HuGENet, 2006; www.cdc.gov/genomics/hugenet/default.htm.
21. Centers for Medicare and Medicaid Services. CLIA program, 2005; www.cms.hhs.gov/clia/.
22. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004;291:2821-7.
23. Chernew ME, Jacobson PD, Hofer TP, Aaronson KD, Fendrick AM. Barriers to constraining health care cost growth. Health Affairs 2004;23:122-8.
24. Collins FS, Green ED, Guttmacher AE, Guyer MS. US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003;422:835-47.
25. Consortium on Pharmacogenetics. Pharmacogenetics: ethical and regulatory issues in research and clinical practice. Minneapolis: University of Minnesota Center for Bioethics, 2002; www.bioethics.umn.edu/news/pharm_report.pdf.
26. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Affairs 2001;5:11-29.
27. Dervieux T, Bala MV. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006;7:1175-84.
28. Diller W. Roche's challenging biomarker strategy. In Vivo: The Business and Medicine Report 2004:53-65.
29. Eisenberg RS. Will pharmacogenomics alter the role of patents in drug development? Pharmacogenomics 2003;3:571-4.
30. Emilien G, Ponchon M, Caldas C, et al. Impact of genomics on drug discovery and clinical medicine. Q J Med 2000;93:391-423.
31. Esteva FJ, Cheli CD, Pritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7:R436-43.
32. Evans BJ, Meslin EM. Encouraging translational research through harmonization of FDA and Common Rule informed consent requirements for research with banked specimens. J Leg Med 2006;27:119-66.
33. Evans BJ. What will it take to reap the clinical benefits of pharmacogenomics? Food Drug Law J 2006;61(4):753-94.
34. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464-8.
35. Farrall M, Morris AP. Gearing up for genome-wide gene-association studies. Hum Mol Genet 2005;14(R2):R157-62.
36. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004;22:481-93.
37. Food and Drug Administration. Annual report to Congress. Office of Combination Products, 2003; www.fda.gov/oc/combination/Congressreport.pdf.
38. Food and Drug Administration. Clinical Pharmacology Subcommittee, Final report of meeting, November 3-4, 2004; www. fda.gov/OHRMS/DOCKETS/ac/04/minutes/ 2004-4079M 1.htm.
39. Food and Drug Administration. Critical Path Initiative: what it means for pharmaceutical industry statisticians. FDA/Industry Workshop September 14-16, 2005. Alexandria, VA: American Statistical Association, 2005; www.amstat.org/meetings/fda-workshop/presentations/2005/ G1_Offen_Critical%20Path.ppt.
40. Food and Drug Administration. Draft guidance: commercially distributed analyte specific reagents (ASRs): frequently asked questions; www.fda.gov/cdrh/oivd/guidance/1590.pdf.
41. Food and Drug Administration. Draft guidance: pharmacogenetic tests and genetic tests for heritable markers; www.fda.gov/cdrh/oivd/guidance/1549.pdf.
42. Food and Drug Administration. Draft guidance: in vitro diagnostic multivariate index assays, 2006; www.fda.gov/cdrh/oivd/guidance/1610.pdf.
43. Food and Drug Administration. Draft guidance: pharmacogenomic data submissions, 2003; www.fda.gov/cder/guidance/5900dft.pdf.
44. Food and Drug Administration. Drug-diagnostic co-development concept paper (draft); www.fda.gov/cder/genomics/pharmacoconceptfn.pdf.
45. Food and Drug Administration. PDA and the Critical Path Institute announce Predictive Safety Testing Consortium; www.fda.gov/bbs/topics/news/2006/ NEW01337.html.
46. Food and Drug Administration. FDA approves heart drug for black patients. PDA Consumer Magazine, 2005; www. fda.gov/fdac/features/2005/505_BiDil.html.
47. Food and Drug Administration. PDA clears breast cancer specific molecular prognostic test, 2007; www.fda.gov/bbs/topics/NEWS/2007/NEW01555.html.
48. Food and Drug Administration. Guidance for industry: collection of race and ethnicity data in clinical trials, 2005; www.fda.gov/cber/gdlns/racethclin. htm.
49. Food and Drug Administration. Guidance on informed consent for in vitro diagnostic device studies using leftover human specimens that are not individually identifiable; http://crpac.od.nih.gov/ FinalFDAGuidanceonICforIVDDeviceStudieswithLeftoverSpecimensthatAreNot IndividuallyIdentifiable.pdf.
50. Food and Drug Administration. Camptosar® (irinotecan HCl): hepatic dysfunction, pancreatitis, UGT1A1, July 21, 2005. Final label; www.fda.gov/cder/foi/label/2005/020571s024,027,0281bl.pdf.
51. Food and Drug Administration. Overview of the Office of Combination Products, 2006; www.fda.gov/oc/combination/overview.html.
52. Food and Drug Administration. The Critical Path to new medical products, 2006; http://www.fda.gov/oc/initiatives/criticalpath/.
53. Food and Drug Administration. The future of drug safety - promoting and protecting the health of the public: FDA's response to the Institute of Medicine's 2006 report, 2007; www.fda.gov/oc/reports/iom013007.pdf.
54. Food and Drug Administration. MedWatch; www.fda.gov/medwatch/What.htm.
55. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004;5:571-9.
56. Garrison LP Jr, Austin MJ. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs 2006;25:1281-1290.
57. Genentech. About Herceptin; www.herceptin.com/herceptin/patient/about/ herceptin.jsp.
58. Genetic Association Information Network (GAIN). Bethesda, MD: Foundation for the National Institutes of Health, 2006; www. fninh.org/GAIN/Gain_home. shtml.
59. Genetics and Public Policy Center. Genetic testing practice guidelines: translating genetic discoveries into clinical care, 2006; www.dnapolicy.org/ resources/Genetic_Testing_Practice_Guideslines.pdf.
60. Gibbs JN. Regulations & standards: the past, present, and future of ASRs. Medical Devicelink, 2003; www.devicelink. com/ivdt/archive/03/11/012.html.
61. Gilbertson JR, et al. Automated clinical annotation of tissue bank specimens. MedInfo 2004:607-610. Pittsburgh, PA: Pennsylvania Cancer Alliance; http://pcabc.upmc.edu/publications/Medinfo2004_5711Gilbertson.pdf.
62. Ginsburg GS, Angrist M. The future may be closer than you think: a response from the Personalized Medicine Coalition to the Royal Society's report on personalized medicine. Future Med 2006;(3):119-23.
63. Goldman BR. Pharmacogenomics: privacy in the era of personalized medicine. NW J Tech Intell Prop 2005;4(1):83-99.
64. Goldstein DB. The genetics of human drug response. Philos Trans R Soc Lond B Biol Sci 2005:29;360:1571-2.
65. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-customer advertising for clinical genetic testing. JAMA 2002; 288(14):1762-7.
66. Goodman C, Faulkner E, Gould C, et al. The value of diagnostics: innovation, adoption, and diffusion into health care. Washington, DC: The Advanced Medical Technology Association, 2005; www.advamed.org/publicdocs/ thevalueofdiagnostics.pdf.
67. Gottlieb S. Speech before 2006 conference on adaptive trial design, Washington DC. Rockville, MD: FDA, 2006; www. fda.gov/oc/speeches/2006/ trialdesign0710.html.
68. Government Accountability Office. New drug development: science, business, regulatory, and intellectual property issues cited as hampering drug development efforts, 2006; www.gao.gov/new.items/d0749.pdf.
69. Grol R, Jalhuijsen J, Thomas S, et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998;317:858-61.
70. Gud J, Bagatto D. Theragenomic knowledge management for individualized safety of drugs, chemicals, pollutants and dietary ingredients. Expert Opin Drug Metal Boxicol 2005;1:537-54.
71. Gunderson KL, Kuhn KM, Steemers FJ, et al. Whole-genome genotyping of haplotype tag single nucleotide polymorphisms. Pharmacogenomes 2006;7:641-8.
72. Gurwitz D, Lunshof JE, Airman RB. A call for the creation of personalized medicine databases. Nat Rev Drug Discov 2006;5:23-6.
73. Gutman SI. FDA's role in the regulation of in vitro diagnostic. Center for Devices and Radiological Health, Office of In Vitro Device Evaluation and Safety, 2003; www.fda.gov/cdrh/oivd/presentations/051003-gutman-1.html.
74. Haga S, Venter C. FDA races in wrong direction. Science 2003;301:466.
75. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 2006;16:847-54.
76. Hampton T. Researchers draft guidelines for clinical use of pharmacogenomics. JAMA 2006;296:3-4.
77. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
78. Herper M. Race-based medicine arrives. New York, NY: Forbes, 2005; www.forbes.com/home/healthcare/2005/05/10/cx_mh_0509racemedicine.html.
79. Hoffman MA. The genome-enabled electronic medical record. J Biomed Informat 2006 [Epub ahead of print].
80. Holtzman NA. FDA and the regulation of genetic tests. Jurimetrics J 2000;41:53-62.
81. Hopkins MM, Ibarreta D, Gaisser S, et al. Putting pharmacogenetics into practice. Nat Biotechnol 2006;24:403-10.
82. International HapMap Project. Cold Spring Harbor, NY: International HapMap Consortium, 2007; www.hapmap.org/.
83. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nature 2002;1:300-8.
84. Issa AM. Pharmacogenomic profiling in post-marketing surveillance: prospects and challenges. Pharmacogenomics 2003;4:647-55.
85. Jain KK. Applications of AmpliChip CYP450. Mol Diagn 2005;9:119-27.
86. Joly Y, Knoppers BM, Nguyen MT. Stored tissue samples: through the confidentiality maze. Pharmacogenomics J 2005;5:2-5.
87. Joly Y, Knoppers BM. Pharmacogenomic data sample collection and storage: ethical issues and policy approaches. Pharmacogenomics 2006;7:219-26.
88. Kahn J. Genes, race and population: avoiding a collision of categories. Am J Public Health 2006;96:1965-70.
89. Kahn J. Patenting race. Nat Biotechnol 2006;24:1349-51.
90. Katz DA. From bench to bedside: a diagnosis framework for pharmacogenetics research. Mol Genet Metab 2002;77:57-60.
91. Kirchheiner J, Fuhr U, Brockmiller J. Pharmacogenetics-based therapeutic recommendations: ready for clinical practice? Nature 2005;4:639-47.
92. Kuehn BM. Industry, FDA warm to "adaptive" trials. JAMA 2006;296:1955-7.
93. Lee SS. Racializing drug design: implications of pharmacogenomics for health disparities. Am J Public Health 2005;95:2133-8.
94. Lehrman S. Jewish leaders seek genetic guidelines. Nature 1997;389:322.
95. Lerman C, Hughes C, Trock BJ, et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 1999;281:1618-22.
96. Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002;2:20-4.
97. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discovery 2004;3:763-9.
98. Lin Z, Owen AB, Altman RB. Genetics. Genomic research and human subject privacy. Science 2004;305(5681):183.
99. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
100. Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses? Am J Law Med 2005;31:365-80.
101. Luce BR. What will it take to make cost-effectiveness analysis acceptable in the United States? Med Care 2005;43(7): II-44-8.
102. Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff 2003;22:31-41.
103. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45.
104. Melzer D, Detmer D, Zimmern R. Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics 2003;4:1-3.
105. Melzer D, Raven A, Detmer DE, et al. My very own medicine: what must I know? Information policy for pharmacogenetics. Cambridge, UK: University of Cambridge, Department of Public Health and Primary Care, 2003.
106. Melzer D, Raven A, Ling T, Detmer D, Zimmern R. Pharmacogenetics: policy needs for personal prescribing. J Health Serv Res Policy 2005;10:40-4.
107. Merrill RA. Genetic testing: a role for FDA? Jurimetrics J 2000;41:63-6.
108. National Academy of Clinical Biochemistry: Guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice, 2006; www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/DraftGuidelines/ Pharmacogenetics/.
109. National Bioethics Advisory Commission. Ethical and policy issues in research involving human participants, 2001; www.georgetown.edu/research/nrcbl/ nbac/human/oversumm.html.
110. National Bioethics Advisory Committee. Research involving human biological materials: ethical issues and policy guidance, 1999 Vol. 1; www.georgetown.edu/research/nrcbl/nbac/hbm_exec.pdf.
111. National Cancer Institute. Cancer Biomedical Informatics Grid (caBIG) 2007; http://cabig.cancer.gov/index.asp.
112. National Human Genome Research Initiative. Summary of the NHGRI workshop on privacy, confidentiality and identifiability in genomic research. Bethesda, October 3-4, 2006; http://www.genome.gov/19519198.
113. National Institute of General Medical Sciences. Pharmacogenetics Research Network; www.nigms.nih.gov/Initiatives/PGRN/.
114. National Institutes of Health. About dbGaP. National Center for Biotechnology Information, 2007; www.ncbi.nlm.nih.gov/entrez/query/Gap/gap_tmpl/ about.html.
115. National Institutes of Health. Clinical Research Policy Analysis & Coordination, 2006; http://crpac.od.nih.gov/about.asp.
116. National Institutes of Health. The Genes and Environment Initiative (GEI), 2006; www.gei.nih.gov/.
117. National Institutes of Health. Genome-Wide Association Studies (GWAS). Bethesda, MD: Office of Extramural Research; http://grants.nih.gov/grants/gwas/ index.htm; Fact Sheet on genome-wide association studies (GWAS) proposed policy, 2006; http://grants.nih.gov/gwas/fact_sheet.htm.
118. National Institutes of Health. One size does not fit all: the promise of pharmacogenomics, 2007; www.ncbi.nlm.nih.gov/About/primer/pharm.html.
119. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat Genet 2005;37:671-81.
120. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. London, England: Nuffield Council on Bioethics, 2003.
121. Office for Human Research Protections. Guidance on research involving coded private information or biological specimens; www.hhs.gov/ohrp/ humansubjects/guidance/cdebiol.htm.
122. Office of the National Coordinator for Health Information Technology (ONCHIT). Consolidated Health Informatics. Washington, DC: DHHS 2006; www.hhs.gov/healthit/chiinitiative.html.
123. Ossorio PN. Product liability for predictive genetic tests. Jurimetrics J 2001;41:239-60.
124. Ozdemir V, Williams-Jones B, Cooper DM, et al. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007;8:177-85.
125. Parent A, Noiseux M, CìtÇ G. Potential for pharmacogenomics science and technology in Canada: pharmaceutical mirage or oasis? Montreal, Quebec: Science-Metrix, Canadian Biotechnology Secretariat, 2004; www.sciencemetrix.com/pdf/SM_2003_015_IC_Pharmacogenomics_Potential_Canada.pdf.
126. Pharmacogenetics: ethical and regulatory issues in research and clinical practice, 2002.
127. PharmGKB: The Pharmacogenetics and Pharmacogenomics Knowledge Base. Palo Alto, CA: Stanford University, 2006; www.pharmgkb.org/index.jsp.
128. Phillips KA, Flatt SJ, Morrison KR, Coates TJ. Potential use of home HIV testing. N Engl J Med 1995;332:1308-10.
129. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004;5:1139-49.
130. Phillips KA, Van Bebber SL. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev 2006;63:301-26.
131. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286;2270-9.
132. Phillips KA, Veenstra DL, Ramsey SD, et al. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004;10:425-32.
133. Pincock S. Pharma goes open access: Novartis shares diabetes genomic data, and experts say there's more to come. The Scientist 2007; www.the-scientist.com/news/home/52891/.
134. Pollack A. A special drug just for you, at the end of a long pipeline. New York Times, November 8, 2005. Prescription Drug Use Fee Act. 72(9) FR 1743-53, 2007.
135. PricewaterhouseCoopers: Personalized Medicine: the Emerging Pharmacogenomics Revolution. New York, 2005; www.pwc. com/techforecast/pdfs/ pharmaco-wb-x.pdf.
136. Puckrein G. BiDil: from another vantage point. Health Aff 2006:w368-w374.
137. Rados C. Advisory committees: critical to the PDA's product review process. FDA Consumer Magazine, 2004; www.fda. gov/fdac/features/2004/104_adv. html.
138. Rawson K. Reimbursing designer drugs. The RPM Report 2006;1(10):19-24. Norwalk, CT: Windhover Information, Inc.
139. Ray T. New FDA guidance will make genetic data more prominent in drug labels. GenomeWeb Daily News February 28, 2007; www.genomeweb.com/issues/news/ 138673-1.html.
140. Regnstrom K, Burgess DJ. Pharmacogenomics and its potential impact on drug and formulation development. Crit Rev Ther Drug Carrier Syst 2005;22:465-92.
141. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
142. Robertson JA, Baruch B, Buchanan A, et al. Pharmacogenetic challenges for the heath care system. Health Aff 2002;21:155-67.
143. Robertson JA, Brody B, Buchanan A, Kahn J, McPherson E. Pharmacogenetic challenges for the health care system. Health Affairs 2002;21:155-67.
144. Roden DM, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-57.
145. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15:1-5.
146. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001;2:228-31.
147. Royal Society: A roadmap for the integration of genetics and genomics into health and society, 2004; Personalised medicines: hopes and realities, 2005; www.royalsoc.ac.uk/displaypagedoc.asp?id=15874.
148. Sadee W. Pharmacogenomics: the implementation phase. AAPS PharmSci 2002;4:1-6.
149. Salerno RA, Lesko LJ. Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission (GDS) proposal. Pharmacogenomics 2004;5:25-30.
150. Sankar P, Kahn J. BiDil: race medicine or race marketing? Health Aff (Millwood) 2005 [Epub ahead of print].
151. Schmedders M, van Aken J, Feuerstein G, et al. Individualized pharmacogenetic therapy: a critical analysis. Community Genet 2003;6:114-9.
152. Secretary's Advisory Committee on Genetics, Health, and Society. Transcript of ninth meeting. March 27, 2006; www4.od.nih.gov/oba/SACGHS/ meetings/March2006/transcripts/FullDayTranscript03-27.pdf.
153. Secretary's Advisory Committee on Genetics, Health, and Society. Coverage and reimbursement of genetic tests and services. Washington, DC: United States Department of Health and Human Services, 2006; www4.od.nih.gov/oba/sacghs/ reports/CR_report.pdf.
154. Secretary's Advisory Committee on Genetics, Health, and Society. Federal oversight of genetic tests and genetic testing laboratories, 2006.
155. Shah J. Pharmacogenetics: ethical issues, 2003.
156. Shah J. Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ 2004;328:1482-6.
157. Shah J. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nat Biotechnol 2003;21:747-53.
158. Shah RR. Can pharmacogenomics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908.
159. Shanawani H, Dame L, Schwartz DA et al. Non-reporting and inconsistent reporting of race and ethnicity in articles that claim associations among genotype, outcome, and race or ethnicity. J Med Ethics 2006;32:724-8.
160. Siegel JE. Cost-effectiveness analysis in US healthcare decision-making: where is it going? Med Care 2005;43(7):II-1-4.
161. Snyderman R, Williams RS. Prospective medicine: the next health care transformation. Acad Med 2003;78(11):1079-84.
162. Spear BB, Health-Chiozzi M, Fugg J. Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201-204.
163. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
164. Sujansky WV. The benefits and challenges of an electronic medical record: much more than a "word-processed" patient chart. West J Med 1998;169:176-83.
165. Sussman S, Valente TW, Rohrbach LA, et al. Translation in the health professions: converting science into action. Eval Health Prof 2006;29:7-32.
166. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med 2003;5:70-6.
167. Szefler SJ, Apter A. Advances in pediatric and adult asthma. J Allergy Clin Immunol 2005;115:470-7.
168. Taulbee P. FDA proposes streamlining intercenter agreements on combo products. The Gray Sheet October 9, 2006;32(041):14.
169. Teutsch SM, Berger ML. Misaligned incentives in America's health: who's minding the store? Ann Fam Med 2005;3:485-7.
170. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5352-8.
171. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. J Natl Cancer Inst 2006;98:116-22.
172. Tucker G. Pharmacogenetics-expectations and reality. BMJ 2004;329:4-6.
173. U.K. National Health Service: Our inheritance, our future: realising the potential of genetics in the NHS, 2003; www.dh.gov.uk/assetRoot/04/01/92/39/ 04019239.pdf.
174. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000;2(3):E29.
175. Vyas H, Summers R. An information-driven approach to pharmacogenomics. Pharmacogenomics 2005;6(5):473-80.
176. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005;6:109-18.
177. Weber W. Pharmacogenetics. New York, NY: Oxford University Press, 1997.
178. Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004;5:663-9.
179. Wechsler J. Drug development linked more closely to diagnostics: manufacturers may need to produce diagnostic tests to gain FDA approval of new pharmacogenomic-based drugs and biologies. Pharmaceutical Technology; Oct 2004.
180. Westfall JM, Mold J, Fagnan L. Practice-based research-"Blue Highways" on the NIH roadmap. JAMA 2007;297:403-6.
181. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
182. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
183. Wolman DM, Kalfoglou AL, Leroy L. Medicare laboratory payment policy now and in the future. Washington, DC: Institute of Medicine, Committee on Medicare Payment Methodology for Clinical Laboratory Services, 2000; www.iom.edu/report. asp?id=5547.
184. Wood AJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2006;355:618-23.
185. Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 2003:72:636-49.
186. Zineh I, Pebanco GD, Aquilante CL, et al. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother 2006;40:639-44.